XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy
09 mars 2023 07h30 HE
|
XOMA Corporation
2022 was the first year with cash receipts from a commercial asset since becoming a royalty aggregator Ebopiprant royalty and milestone license acquisition gives XOMA the potential to earn up to $378...
XOMA to Present at 43rd Annual Cowen Health Care Conference
28 févr. 2023 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today that Owen Hughes, Executive Chairman, and Brad Sitko, Chief...
XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 janv. 2023 19h00 HE
|
XOMA Corporation
EMERYVILLE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”), the Biotech Royalty Aggregator, today announced the Company has granted Owen Hughes,...
New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy
04 janv. 2023 07h30 HE
|
XOMA Corporation
Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:...
XOMA Declares Quarterly Preferred Stock Dividends
22 déc. 2022 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
22 nov. 2022 07h01 HE
|
XOMA Corporation
XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay Potential to earn $475...
XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events
03 nov. 2022 07h30 HE
|
XOMA Corporation
Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). First five...
XOMA Declares Quarterly Preferred Stock Dividends
21 sept. 2022 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends...
XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...
XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events
04 août 2022 07h30 HE
|
XOMA Corporation
The completion of Regeneron’s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5 million of which was paid to XOMA in July. Data from Rezolute and Day...